- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Swiss Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Results
16
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
16 companies
Bachem Holding
Market Cap: CHF 4.0b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 53.40
7D
-0.3%
1Y
-17.1%
Basilea Pharmaceutica
Market Cap: CHF 666.0m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 54.20
7D
3.4%
1Y
28.6%
Molecular Partners
Market Cap: CHF 123.4m
A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
MOLN
CHF 3.30
7D
-1.6%
1Y
-28.6%
Cosmo Pharmaceuticals
Market Cap: CHF 1.6b
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.
COPN
CHF 97.50
7D
-6.8%
1Y
61.4%
Tecan Group
Market Cap: CHF 1.6b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 125.30
7D
-4.9%
1Y
-39.2%
SKAN Group
Market Cap: CHF 1.1b
Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.
SKAN
CHF 49.55
7D
-1.9%
1Y
-31.4%
Kuros Biosciences
Market Cap: CHF 1.1b
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 28.42
7D
-5.5%
1Y
31.6%
Dottikon ES Holding
Market Cap: CHF 4.6b
Manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical maceutic industries in Europe, Switzerland, the United States, and Asia.
DESN
CHF 331.50
7D
-4.1%
1Y
49.0%
Addex Therapeutics
Market Cap: CHF 6.3m
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland.
ADXN
CHF 0.054
7D
1.9%
1Y
-8.5%
BioVersys
Market Cap: CHF 143.3m
A clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria.
BIOV
CHF 24.50
7D
6.1%
1Y
n/a
Roche Holding
Market Cap: CHF 275.3b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROG
CHF 321.90
7D
1.3%
1Y
25.6%
Galderma Group
Market Cap: CHF 39.6b
Operates as a dermatology company worldwide.
GALD
CHF 166.70
7D
1.3%
1Y
76.0%
Lonza Group
Market Cap: CHF 36.7b
Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 523.20
7D
-4.6%
1Y
-4.1%
Siegfried Holding
Market Cap: CHF 3.2b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 73.30
7D
1.2%
1Y
-24.7%
Newron Pharmaceuticals
Market Cap: CHF 398.8m
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.
NWRN
CHF 19.98
7D
3.1%
1Y
138.4%
PolyPeptide Group
Market Cap: CHF 818.2m
Operates as a contract development and manufacturing company in Europe, the United States, and India.
PPGN
CHF 24.80
7D
1.6%
1Y
-15.9%